Skip to content

Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients

A Functional Magnetic Resonance Imaging Study to Investigate ATP-sensitive Cough Neural Pathways in Patients With Chronic Cough Hypersensitivity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03722849
Enrollment
58
Registered
2018-10-29
Start date
2019-03-01
Completion date
2022-05-13
Last updated
2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough

Keywords

functional brain imaging, ATP, Capsaicin, Refractory cough

Brief summary

Persistent cough is a distressing symptom for people with respiratory disorders. Patients also often experience an ongoing urge-to-cough that prompts coughing, and which fails to resolve the sensation. Understanding how the brain controls cough and the urge-to-cough could lead to new cough suppressing therapies. The overall objective of this project is to use functional brain imaging (fMRI) to identify brain regions that are involved in the exaggerated urge-to-cough in humans with chronic cough. Our focus will be on the brainstem where information from the airways first arrives in the central nervous system.

Detailed description

Peripheral effects of ATP via P2X3 receptors ATP has been shown to be a tussive agent particularly on chronic cough patients who were more sensitive than non-cough subjects to inhaled ATP. ATP has been shown to augment the cough response to capsaicin in patients with asthma. Gefapixant at a single oral dose of 50 mg did not modulate capsaicin cough responses in normal volunteers and chronic cough subjects while inhibiting ATP-induced cough particularly in chronic cough subjects. These observations would suggest that ATP has a direct effect on a subset sensory neurons that evoke coughing through the activation of P2X3 receptors. The use of fMRI to provide insights into the peripheral and central sites of activation by ATP/P2X3 activation We have generated functional brain imaging (fMRI) data to suggest that the different brain circuits in receipt of nodose and jugular ganglia neuron inputs (as identified in animal studies) are conserved in humans. When inhaled, the tussigenic compound capsaicin (from hot chili peppers) indiscriminately stimulates both nodose and jugular chemosensitive afferents and we have published that capsaicin inhalation produces brain activations in the primary sensory, anterior and mid-insula, cingulate, premotor, motor and orbitofrontal cortices. These regions are presumed to encode perceptual awareness of airway irritation, and the associated emotional, cognitive and behavioral (motor) consequences. For example, activity in the human primary sensory cortex (which receives jugular ganglia inputs in animal studies) correlates with an individual's perception of airway irritation (their perceived need/ urge to cough) while activity in the insula (in receipt of nodose inputs) relates closely to the actual magnitude of the delivered stimulus independent of perception. We have now built upon these published findings by using high resolution brainstem fMRI during the inhalation of ATP (expected to only activate P2X2/3 expressing nodose-derived airway afferents) versus capsaicin (expected to activate both jugular and nodose chemosensitive afferents). Our results are striking and reveal that ATP inhalation evokes an in increased signal level in the brainstem regions corresponding to the nTS, while capsaicin inhalation produces activations in both the nTS and in an area of the dorsal spinal trigeminal nucleus on the lateral margins of the brainstem that contains the paratrigeminal nucleus. Indeed, our healthy participants did not cough as much to ATP compared to capsaicin, consistent with studies cough in animals and humans and the relatively poor cough-evoking properties of ATP in healthy humans. However, the perception of airway irritation was identical between ATP and capsaicin stimuli. We believe that cough production will ultimately be dependent upon activation of the neural circuit that integrates in the paratrigeminal nucleus (i.e.' the jugular afferent pathway) and therefore we hypothesize that there is an upregulation of the capacity of ATP to act via jugular ganglia pathways in chronic cough patients. The fMRI studies described above provide an exciting opportunity to assess for the first time which primary airway afferent pathways are likely excited or sensitized by ATP and, in turn, what aspects of the central processing of airway sensory information is altered by ATP. We have reported previously that patients with chronic cough display functional brain responses consistent with a state of central sensitization that closely resembles the central sensitization accompanying chronic pain. We will extend upon these findings by determining whether ATP-sensitive pathways in the brainstem and brain are altered in patients with chronic cough, and in doing so provide insight into whether ATP effects vagal afferent processing through an interaction with nodose and/ or jugular neural pathways.

Interventions

Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough

DRUGCapsaicin

Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough

Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)

Sponsors

Imperial College London
CollaboratorOTHER
Queen's University, Belfast
CollaboratorOTHER
Monash University
CollaboratorOTHER
Stuart Mazzone
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

The experiment will consist of two sessions. The first session will involve questionnaires, followed by measures of sensitivity and behavioural responses to tussive (cough evoking) stimulation. The second session will involve functional brain imaging measures of responses to tussive stimulation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients with physician diagnosed chronic refractory cough (cough lasting \>8 weeks). * \> 18 years of age * Must be cognitively impaired

Exclusion criteria

* People with contraindications to MRI scanning (i.e. metal implants, claustrophobia). * History of uncontrolled asthma or chronic respiratory disease (other than refractory cough). * Evidence of an allergic reaction to capsaicin (chilli). * Pregnant women. * Smoking, current or recent history (last 6 months).

Design outcomes

Primary

MeasureTime frameDescription
Brainstem Neural Activations to CapsaicinfMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after.fMRI will be used to determine the location and magnitude of neural responses in the brainstem during Capsaicin inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to Capsaicin greater than control saline.
Brainstem Neural Activations to ATPfMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after.fMRI will be used to determine the location and magnitude of neural responses in the brainstem during ATP inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to ATP greater than control saline.

Secondary

MeasureTime frameDescription
Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinThresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanningParticipant responses (cough and the urge-to-cough) evoked by Capsaicin will be measured by counting audible coughs to doubling doses of Capsaicin and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as microM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.
Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPThresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanningParticipant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as milliM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.
Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPUrge-to-cough ratings were reported during the 1 hour cough challenge testing session and during the subsequent fMRI scanning sessionParticipant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose.Urge-to-cough score is reported by the participant using a Bog scale ranging from 0 (no urge) to 10 (most intense urge imaginable) where the higher score, the worse the outcome. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.

Countries

Australia

Participant flow

Recruitment details

All participants were initially screened via telephone interviews for inclusion and exclusion criteria and gave written, informed consent prior to study enrolment. Refractory and unexplained chronic cough were diagnosed by a respiratory or laryngology specialist or general practitioner and inclusion required cough of at least 6 months duration with no abnormalities on chest X-ray or CT scan.

Participants by arm

ArmCount
Chronic Cough Participant
Twenty-nine (29) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), were recruited. Participants attended two sessions. In the first they inhaled in a single breath nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants underwent functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin.
29
Healthy Control Participant
Twenty-nine (29) appropriately age and sex matched healthy non-smoking individuals were recruited as the comparison group. Participants attended two sessions. In the first they inhaled in a single breath nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants underwent functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin.
29
Total58

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject11

Baseline characteristics

CharacteristicHealthy Control ParticipantTotalChronic Cough Participant
Age, Continuous59.7 years
STANDARD_DEVIATION 12
60.1 years
STANDARD_DEVIATION 12
60.6 years
STANDARD_DEVIATION 12.2
Hull Cough Hypersensitivity Questionnaire (HARQ) score2.3 units on a scale
STANDARD_DEVIATION 2.8
17.5 units on a scale
STANDARD_DEVIATION 18.1
33.1 units on a scale
STANDARD_DEVIATION 13.1
Leicester Cough Questionnaire (LCQ) score20.8 units on a scale
STANDARD_DEVIATION 0.3
17.3 units on a scale
STANDARD_DEVIATION 4.5
13.9 units on a scale
STANDARD_DEVIATION 3.6
Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) score20.1 units on a scale
STANDARD_DEVIATION 1.1
17.5 units on a scale
STANDARD_DEVIATION 3.5
14.8 units on a scale
STANDARD_DEVIATION 3
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Australia
29 participants58 participants29 participants
Sex: Female, Male
Female
19 Participants38 Participants19 Participants
Sex: Female, Male
Male
10 Participants20 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 290 / 29
other
Total, other adverse events
0 / 290 / 29
serious
Total, serious adverse events
0 / 290 / 29

Outcome results

Primary

Brainstem Neural Activations to ATP

fMRI will be used to determine the location and magnitude of neural responses in the brainstem during ATP inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to ATP greater than control saline.

Time frame: fMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after.

Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough. 1 participant from each group withdrew prior to completion of the primary endpoint investigation.

ArmMeasureGroupValue (MEAN)Dispersion
Chronic Cough ParticipantBrainstem Neural Activations to ATP%BOLD signal Change: Nucleus of the Solitary Tract0.04 Percent change in BOLD signalStandard Deviation 0.47
Chronic Cough ParticipantBrainstem Neural Activations to ATP%BOLD signal Change: Paratrigeminal Nucleus0.01 Percent change in BOLD signalStandard Deviation 0.65
Healthy Control ParticipantBrainstem Neural Activations to ATP%BOLD signal Change: Nucleus of the Solitary Tract0.28 Percent change in BOLD signalStandard Deviation 0.58
Healthy Control ParticipantBrainstem Neural Activations to ATP%BOLD signal Change: Paratrigeminal Nucleus0.58 Percent change in BOLD signalStandard Deviation 0.71
Comparison: Mann-Whitney U tests for non-parametric datap-value: =0.007Wilcoxon (Mann-Whitney)
Primary

Brainstem Neural Activations to Capsaicin

fMRI will be used to determine the location and magnitude of neural responses in the brainstem during Capsaicin inhalation: in particular, the nucleus of the solitary tract and the paratrigeminal nucleus. fMRI non-invasively measures Blood Oxygen Level Dependent (BOLD) signals in the brain which can be used to identify regions of the brain that increase activity associated with the inhaled stimuli. BOLD signals detected are to be reported as % BOLD signal change in response to Capsaicin greater than control saline.

Time frame: fMRI was performed in a single session on the day of the cough challenge testing session and not more than seven days after.

Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough. 1 participant from each group withdrew prior to completion of the primary endpoint investigation.

ArmMeasureGroupValue (MEAN)Dispersion
Chronic Cough ParticipantBrainstem Neural Activations to Capsaicin%BOLD signal Change: Nucleus of the Solitary Tract0.09 Percentage change in BOLD signalStandard Deviation 0.6
Chronic Cough ParticipantBrainstem Neural Activations to Capsaicin%BOLD signal Change: Paratrigeminal Nucleus-0.14 Percentage change in BOLD signalStandard Deviation 0.69
Healthy Control ParticipantBrainstem Neural Activations to Capsaicin%BOLD signal Change: Nucleus of the Solitary Tract0.39 Percentage change in BOLD signalStandard Deviation 0.47
Healthy Control ParticipantBrainstem Neural Activations to Capsaicin%BOLD signal Change: Paratrigeminal Nucleus0.44 Percentage change in BOLD signalStandard Deviation 1.06
Comparison: Mann-Whitney U tests for non-parametric datap-value: =0.0028Wilcoxon (Mann-Whitney)
Secondary

Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATP

Participant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as milliM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.

Time frame: Thresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanning

Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough.

ArmMeasureGroupValue (MEAN)Dispersion
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP Urge to Cough threshold Cu1.29 milliMStandard Error 4.27
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP Cough threshold C25.75 milliMStandard Error 7.08
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP maximum tolerable dose Smax2.82 milliMStandard Error 5.75
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP fMRI dose2.82 milliMStandard Error 5.5
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP fMRI dose12.02 milliMStandard Error 4.47
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP Urge to Cough threshold Cu2.75 milliMStandard Error 3.63
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP maximum tolerable dose Smax19.95 milliMStandard Error 5.89
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to ATPATP Cough threshold C257.54 milliMStandard Error 4.79
Secondary

Behavioral Responses During Cough Challenge Testing: Cough Sensitivity to Capsaicin

Participant responses (cough and the urge-to-cough) evoked by Capsaicin will be measured by counting audible coughs to doubling doses of Capsaicin and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose. Thresholds for cough sensitivity are to be reported as microM. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.

Time frame: Thresholds for cough sensitivity were measured during a 1 hr session prior to fMRI scanning

Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough.

ArmMeasureGroupValue (MEAN)Dispersion
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin Cough threshold C23.80 microMStandard Error 4.9
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin maximum tolerable dose Smax0.91 microMStandard Error 4.27
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin fMRI dose0.79 microMStandard Error 4.17
Chronic Cough ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin Urge to Cough threshold Cu0.91 microMStandard Error 5.25
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin Urge to Cough threshold Cu2.00 microMStandard Error 2.75
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin Cough threshold C212.89 microMStandard Error 2.75
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin fMRI dose1.66 microMStandard Error 3.39
Healthy Control ParticipantBehavioral Responses During Cough Challenge Testing: Cough Sensitivity to CapsaicinCapsaicin maximum tolerable dose Smax3.02 microMStandard Error 3.47
p-value: =0.0019ANOVA
Secondary

Behavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATP

Participant responses (cough and the urge-to-cough) evoked by ATP will be measured by counting audible coughs to doubling doses of ATP and by asking participants to rate their perception of urge-to-cough using visual analogue scales (VAS) to each dose.Urge-to-cough score is reported by the participant using a Bog scale ranging from 0 (no urge) to 10 (most intense urge imaginable) where the higher score, the worse the outcome. Cu is the threshold dose required to elicit a non-zero urge-to-cough rating. C2 is the threshold dose required to elicit two audible coughs. Smax is the largest dose that could be inhaled for 24s without eliciting an audible cough. fMRI dose was the dose used during fMRI scanning.

Time frame: Urge-to-cough ratings were reported during the 1 hour cough challenge testing session and during the subsequent fMRI scanning session

Population: Cough participants displayed characteristic signs and symptoms of refractory chronic cough.

ArmMeasureGroupValue (MEAN)Dispersion
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPATP Urge to Cough rating at Cu2.31 Score on a scaleStandard Error 2.12
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPCapsaicin fMRI urge to cough rating3.65 Score on a scaleStandard Error 2.06
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPCapsaicin Urge to Cough rating at C24.48 Score on a scaleStandard Error 2.32
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPATP fMRI urge to cough rating2.90 Score on a scaleStandard Error 1.41
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPATP Urge to Cough rating at C25.03 Score on a scaleStandard Error 2.57
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPSaline fMRI urge to cough rating0.86 Score on a scaleStandard Error 1.2
Chronic Cough ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPCapsaicin Urge to Cough rating at Cu2.07 Score on a scaleStandard Error 2.03
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPSaline fMRI urge to cough rating0.44 Score on a scaleStandard Error 0.71
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPCapsaicin Urge to Cough rating at Cu1.61 Score on a scaleStandard Error 1.47
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPCapsaicin Urge to Cough rating at C26.80 Score on a scaleStandard Error 2.29
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPATP Urge to Cough rating at Cu1.80 Score on a scaleStandard Error 1.65
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPATP Urge to Cough rating at C26.43 Score on a scaleStandard Error 2.26
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPCapsaicin fMRI urge to cough rating3.89 Score on a scaleStandard Error 1.97
Healthy Control ParticipantBehavioral Responses to Cough Challenge Testing: Urge to Cough Ratings to Capsaicin and ATPATP fMRI urge to cough rating3.93 Score on a scaleStandard Error 2.1
p-value: <0.0001ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026